Biostem Technologies (BSEM) Company presentation summary

Mission and market opportunity

• Focused on delivering advanced wound healing technologies to improve patient outcomes.

• Addresses a large, underserved US soft tissue allograft market estimated at $23B, spanning orthopedics, wound care, urology, spine, and women's health.

• Regenerative medicine solutions aim to accelerate healing, minimize complications, and reduce healthcare costs.

Financial performance and outlook

• Reported Q1 2026 revenue of $6.1M with a 61% gross margin and $13.7M in cash.

• FY26 revenue guidance set at $25–$29M, with a track record of positive adjusted EBITDA and cash flow.

• Acquired assets generated $29M in 2025 and are expected to remain resilient to CMS price changes.

Strategic initiatives and corporate developments

• Closed acquisition of BioTissue's surgical and wound care business, expanding product portfolio and direct sales force.

• Progressed toward Nasdaq uplisting with completed audits and a confidential Form 10 filing.

• Strengthened balance sheet by retiring debt and closing a $2.5M PIPE with an institutional investor.

• Expanded leadership team and board with experienced industry professionals.